MAZENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Maze Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$29.70+2.17 (+7.88%)
Close on Oct 19, 2026
- Market cap
- $1.75B
- P/E (TTM)
- –
- Dividend yield
- –
Maze Therapeutics, Inc. revenue by segment
By business segment
By product or service
By region
From the segment and revenue-disaggregation notes of Maze Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.